Join Our Mailing List:
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
Featured Events
View All Events
Jae Yeon Jung , M.D., Ph.D.
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Breast Cancer
Award Year: 2015


Career Summary: Dr. Jung is an Assistant Professor of Dermatology and a member of the Cancer Immunotherapeutics Program at the City of Hope National Medical Center. Her primary research focuses on developing novel immunotherapy treatments for breast cancer patients. Skin metastases are common in breast cancer patients and are often the first site of disease recurrence. They can also be extensive and morbid in patients who do not respond to treatment. While treating these extensive ulcers from breast cancer metastases, she has developed therapeutic strategies that can help the immune system target breast cancer cells. With her background in melanoma immunotherapy research and clinical training as a dermatologist, she has a unique perspective that she is now applying to breast cancer immunotherapy research.

Dr. Jung completed medical school, a doctorate in Molecular Biology and her residency training in Dermatology at Washington University in Saint Louis, Missouri. She furthered her training with additional postdoctoral fellowships in melanoma immunotherapy and tumor biology at the Malaghan Institute in Wellington, New Zealand and the University of Utah in Salt Lake City, Utah. She has been a co-investigator on grant from the NIH, and received an NIH pre-doctoral National Research Service Award. She is also a recipient of the Dermatologist Investigator Research Fellowship Award from the Dermatology Foundation.

Year STOP CANCER Award was received:  2015 Marni Levine Memorial Seed Grant

Description of research performed: The overall goal of our project is to develop a treatment for metastatic breast cancer that can harness the power of our own immune system to help destroy tumor cells.   By treating tumor cells in the skin with cryotherapy and a combination of immune modulators, the immune system can be “trained” to detect and kill breast cancer cells both locally and systemically.  Correlative studies will evaluate the development of tumor infiltrating lymphocytes, which are key prognostic markers for response to treatment and overall survival. 

Results of research: The results from this pilot study will be used to define an immunotherapy protocol that can be used for many different types of breast cancer and will be especially effective for treating patients that are unable to receive targeted therapies or have failed traditional therapy.


STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2018 STOP CANCER. All Rights Reserved. | Privacy Policy